Novel strategies for the treatment of sepsis.
The history of therapeutic interventions in clinical trials for sepsis has been referred to as the "graveyard for pharmaceutical companies." That is now set to change, as research provides hope for new approaches that will be therapeutically effective in humans with sepsis.
Riedemann
Niels C
NC
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Guo
Ren-Feng
RF
Ward
Peter A
PA
D000818:Animals; D015703:Antigens, CD; D017209:Apoptosis; D015936:Complement C5a / Q000037:antagonists & inhibitors; D024243:HMGB1 Protein / Q000502:physiology; D006801:Humans; D008263:Macrophage Migration-Inhibitory Factors / Q000502:physiology; D011486:Protein C / Q000627:therapeutic use; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement / Q000037:antagonists & inhibitors; D018805:Sepsis / Q000188:drug therapy* / Q000209:etiology
D015703:Antigens, CD; D024243:HMGB1 Protein; D008263:Macrophage Migration-Inhibitory Factors; D011486:Protein C; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement; D015936:Complement C5a